successful applications from eu12 countries & tips for success imi open info day, bucharest 10...
Post on 11-Jan-2016
217 Views
Preview:
TRANSCRIPT
Successful applications from EU12 countries & Tips for success
IMI Open Info Day, Bucharest 10 December 2012
Magali Poinot, Legal ManagerAngela Wittelsberger, Scientific Project Manager
Participants from EU12 countries in IMI projects
IMI Open Info Day, Bucharest 10 December 2012
Project Acronym
Research field Coordinator/ Managing Entity
Legal Name City Country
PROTECT Pharmacoepidemiological Research
EMA/DKMA-Danish Medicines Agency
Poznan University of Medical Sciences
Poznan Poland
U-BIOPRED Biomarkers for the Prediction of Respiratory Disease Outcomes
Novartis/Amsterdam Medical Center
Uniwersytet Jagiellonski Krakow Poland
Semmelweis University Budapest Hungary
Pharmatrain Pharmaceutical Medicine Training Programme
European Federation of Courses/University Basel
Semmelweis University Budapest HungaryFaculty of Medicine University of Belgrade
Belgrade Serbia
EMTRAIN European Medicines Research Training Network
AstraZeneca/Medical University Vienna
Ministry of Human Resources, Medical Research Council
Budapest Hungary
BTCURE BeTheCure UCB/Karolinska Institute
Revmatologicky ustav Praha Czech Republic
PREDECT New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours
Servier/University of Helsinki
University of Tartu TARTU Estonia
EHR4CR Electronic Health Record systems for Clinical Research
AstraZeneca/EuroRec Medical University of Warsaw Warsaw Poland
ABIRISK Immugenicity of biopharmaceuticals
GSK/Inserm Univerzita Karlova v Praze Prague 1 Czech Republic
MIP-DILI Prediction of Drug-Induced Liver Injury
AstraZeneca/University of Liverpool
SOLVO BIOTECHNOLOGY ZRT SZEGED Hungary
Compact Macromolecular Pharmaceuticals
Sanofi/University of Utrecht
PHARMACOIDEA Development and Service Ltd.
Szeged Hungary
EMIF European Medical Information Framework
J&J/Erasmus University MC Rotterdam
Tartu Ulikool Tartu Estonia
Unbiased Biomarkers in the Prediction of Respiratory Disease Outcome
The Objective
Developing biomarker profiles from molecular, physiological, and clinical data integrated by into handprints for the prediction of clinical course, therapeutic efficacy and identification of novel targets in the treatment of severe asthma
Progress Developed an international consensus on diagnostic criteria
Creating novel phenotype ‘handprints’ by combining molecular, histological, clinical and patient-reported data – validation and refining is on-going
Two novel animal models have been identified (FCA/HDM, CT & MRI imaging of chronic HDM model)
Preparation and recruitment for cohort clinical study have started, 14 centres across Europe targeting 1025 subjects, to validate the handprints for their predictive efficacy in gold standard and experimental therapeutic intervention
Example: U-BIOPRED
IMI Open Info Day, Bucharest 10 December 2012
University of AmsterdamUniversity of SouthamptonImperial College LondonUniversity of ManchesterUniversity of NottinghamFraunhofer institute HannoverCentr Nat Recherche Sc Villejuif ParisUniversité de Méditerranee MontpellierKarolinska Institute StockholmUniversity UmeaUniversityTor Vergata RomeUniversità Cattolica del Sacro Cuore RomeUniversity of CataniaHvidore Hospital CopenhagenUniversity Hospital CopenhagenHaukeland University BergenSemmelweis University BudapestJagiellonan University KrakowUniversity Hospital BernUniversity of Ghent
NovartisGlaxoSmithKlineAstraZenecaChiesiPfizerRoche UCBBoehringer IngelheimAlmirallJohnson & Johnson / Janssen
BiosciAerocrineSynairgenPhilips Research
Netherlands Asthma FoundationAsthma UKEuropean Lung FoundationEFAInt Primary Care Respir GroupLega Italiano Anti Fumo
U-BIOPRED: participants from EU12 country
IMI Open Info Day, Bucharest 10 December 2012
1. Department of Medicine, University Medical Colloge, Krakow, Poland:
- Role in project: patient cohort building, data analysis- Had multi-center international trial experience- Had existing collaborations with several partners of the
consortium
2. Department of Pulmonology, Semmelweis University, Budapest, Hungary:
- Role in project: patient cohort building, data analysis, pre-clinical laboratory model studies
- Had experience from multiple multi-center international trials- Had existing collaborations with two partners of the consortium
Example: BTCure (Be the Cure)
IMI Open Info Day, Bucharest 10 December 2012
Facts & FiguresStart Date01/04/2011Duration60 months Contributions €IMI funding 16 137 872EFPIA in-kind 14 172 302Other 7 807 923Total Cost 38 118 097
The Objective
• to further broaden our knowledge of disease causing factors and disease progression in Rheumatoid Arthritis (RA), thereby identifying improved or targeted therapeutic treatments
• development of new diagnostic methods to discover the early forms of RA as well as tools to separate the different forms of RA
Strategy
to achieve this goal by using a transnational, collaborative approach and by driving this ambitious project forward in a joint effort
Example: BTCure
EFPIAAstraZeneca AB, SwedenBoehringer Ingelheim International GMBH, GermanyBristol Myers Squibb EMEA sarl, USACENTOCOR B.V., NetherlandsF. Hoffmann-La Roche AG, SwitzerlandMerck, GermanyNovoNordisk A/S, DenmarkPfizer Limited, UKUCB Pharma, SA,Belgium
UNIVERSITIES, RESEARCH ORGANISATIONS, PUBLIC BODIES & NON-PROFITA. Fleming Biomedical Sciences Research Center, GreeceAMC/University of Amsterdam, NetherlandsCharité-University of Medicine, Berlin, GermanyDiakonhjemmet Hospital, NorwayFoundation for Research and Technology, GreeceGerman Rheuma Research Centre Berlin, GermanyHumanitas Foundation for Research, ItalyImperial College London, UKKarolinska Institute, SwedenKing's College London, UKINSERM, FranceNational University of Ireland, DublinPhadia AB, SwedenRevmatologicky Institute, Czech RepublicSpanish National Research Council, SpainStichting Catholic University NetherlandsUniversity College Dublin, Ireland,University Hospital Centre, Montpellier, FranceUniversity Hospital Leiden (LUMC), NetherlandsUniversity of Erlangen, GermanyUniversity of Glasgow, UKUniversity of Leeds, UKUniversity of Manchester, UKUniversity of Zürich, Switzerland
SMEsTcLand Expression, France
BTCure: participant from EU12 country
IMI Open Info Day, Bucharest 10 December 2012
Institute of Rheumatology, Prague, Czech Republic:- Role in project: development of tools to search, access and share
clinical data, development of some other procedures- Previous experience with FP6 project (WP leader)- Participation in other world-wide, EU-wide, and nation-wide
studies
Tips for success
1. Writing a successful proposal
IMI Open Info Day, Bucharest 10 December 2012
Evaluation process
IMI Open Info Day, Bucharest 10 December 2012
• Expressions of Interest (EoIs) are reviewed and ranked by a panel of at least 5 independent experts
• Experts identified by IMI Executive Office
• Experts in the area
• Have no conflicts of interest
Evaluation criteria
IMI Open Info Day, Bucharest 10 December 2012
• Scientific and/or technological excellence
• Excellence of Partnership
• Work-plan outline
• Ethical Issues
Scientific and/or technological excellence
IMI Open Info Day, Bucharest 10 December 2012
• Quality and soundness of the scientific and/or technological approach
• Likelihood of the research proposal to meet all the key objectives in order to complement the EFPIA Consortium.
• Innovation (i.e. novelty in discovery, practical applicability, adaptation, etc.), progress beyond the state-of-the-art.
• Degree of scientific and/or technological impact likely to be delivered?
• Has the Applicant Consortium adequately explained the balance between potential impact and residual risks based on the proposed approach i.e. are potential complications, alternative strategies, and benchmarks for success presented?
Excellence of Partnership
IMI Open Info Day, Bucharest 10 December 2012
• Scientific quality and technological expertise of the individual participants in the Applicant Consortium.
• Ability to provide the contributions expected from the Applicant Consortium.
• Unique features, strengths, internal complementarities and balance of the Applicant Consortium (including appropriate allocation of roles, manageability of consortium and input of each participant).
Work-plan outline / Ethics
IMI Open Info Day, Bucharest 10 December 2012
• Conceptual quality and soundness of the work-plan outline, including approximate budget, timelines for deliverables
• Does this proposal contain ethical issues that may need further attention if selected for Evaluation Stage 2?
Common mistakes
IMI Open Info Day, Bucharest 10 December 2012
• Submission deadline missed
• At the time of submission: parts of the EoI not uploaded (this should not be a problem anymore with SOFIA)
• Applicants are not eligible for funding (enterprises that request but are not eligible for funding can still be partners)
• Legal status of applicants is not clear
• Consortium eligibility criteria not met (e.g., a single legal entity is not a consortium)
• Applicant consortia do not have the capabilities to address all of the objectives (e.g., redundancy between partners)
Common mistakes
IMI Open Info Day, Bucharest 10 December 2012
• Submitted text does not respect the EoI template (sometimes received even slides!)
• Submitted text so concise that it does not clearly state what is proposed in practice
• The EoI does not address all the objectives (addressing almost all the objectives is not sufficient!)
• EoI out of scope (if you have doubts on how to respond to the call contact IMI)
• Ethical issues not addressed
Make sure to:
IMI Open Info Day, Bucharest 10 December 2012
• Read all the Call-relevant material that is provided on the IMI website www.imi.europa.eu
• Understand IMI’s Rules and respect them
• If in doubt ask a member of the IMI Executive Office
• Your EoI should provide reviewers with all the information requested to allow them to evaluate it
• Finalise your submission
• If invited to a hearing answer the questions as precisely and concisely as possible
Tips for success
2. How to be onboard of the winning consortium
IMI Open Info Day, Bucharest 10 December 2012
How to find project partners
1. IMI Partner Search Tool: www.imi.europa.eu/content/partner-search
2. IMI States Representatives Group (SRG) member: www.imi.europa.eu/content/states-representatives-groups
3. Health National Contact Point (NCP): cordis.europa.eu/fp7/health/ncp_en.html
4. Keep up-to-date: • Visit www.imi.europa.eu• Sign up to the IMI Newsletter• Follow us on IMI Twitter: @IMI_JU• Join the IMI group on LinkedIn• Questions? E-mail us: infodesk@imi.europa.eu
IMI Open Info Day, Bucharest 10 December 2012
How to find project partners
1. IMI Partner Search Tool: www.imi.europa.eu/content/partner-search
2. IMI States Representatives Group (SRG) member: www.imi.europa.eu/content/states-representatives-groups
3. Health National Contact Point (NCP): cordis.europa.eu/fp7/health/ncp_en.html
4. Keep up-to-date: • Visit www.imi.europa.eu• Sign up to the IMI Newsletter• Follow us on IMI Twitter: @IMI_JU• Join the IMI group on LinkedIn• Questions? E-mail us: infodesk@imi.europa.eu
IMI Open Info Day, Bucharest 10 December 2012
How to be onboard of the winning consortium:
How to find project partners
1. IMI Partner Search Tool: www.imi.europa.eu/content/partner-search
2. IMI States Representatives Group (SRG) member: www.imi.europa.eu/content/states-representatives-groups
3. Health National Contact Point (NCP): cordis.europa.eu/fp7/health/ncp_en.html
4. Keep up-to-date: • Visit www.imi.europa.eu• Sign up to the IMI Newsletter• Follow us on IMI Twitter: @IMI_JU• Join the IMI group on LinkedIn• Questions? E-mail us: infodesk@imi.europa.eu
IMI Open Info Day, Bucharest 10 December 2012
1. Clearly identify and communicate what you want and can contribute to the objectives of the Call
2. Get in touch pro-actively with the key players in the field
How to be onboard of the winning consortium:
THANK YOU !THANK YOU !
www.imi.europa.eu
IMI Open Info Day, Bucharest 10 December 2012
top related